Ajuda Cristina

AURELIO. 2022. Disponível em: <https://www.dicio.com.br/interativo/>. Acesso em 28 out. 2022.

HAND; MANNILA0; SMYTH, 2001 apud CAMILO; SILVA, 2009

CAMILO, C. O.; SILVA, J. C. Mineração de Dados: Conceitos, Tarefas, Métodos e Ferramentas. Instituto de Informática. Universidade Federal de Goiás. ago. 2009. Disponível em: <https://rozero.webcindario.com/disciplinas/fbmg/dm/RT-INF\_001-09.pdf>. Acesso em: 26 mar. 2019.

LEDÓN; LAGE, 2017;

SCHELLEKENS, H. When biotech proteins go off-patent, 2004. In Biosimilars and the real world. Ledón N., Lage A. MEDICC Review 2017 19:4 (9-14) Disponível em: <https://www.scielosp.org/article/ssm/content/raw/?resource\_ssm\_path=/media/assets/medicc/v19n4/1555-7960-medicc-19-04-0009.pdf>. Acesso em 23 fev. 2019.

OPAS, 2008

ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). **Monitorização da segurança de medicamentos**: diretrizes para criação e funcionamento de um Centro de Farmacovigilância. Brasília: Organização Pan-Americana da Saúde, 2005. 28p

UNITED STATES. Food & Drug Administration (FDA). Demonstration of Comparability of Human Biological Products, including Therapeutic Biotechnology-derived Products. Center for Biologics Evaluation and Research (CBER). Center for Drug Evaluation and Research (CDER). 1996. Disponível em: < https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstration-comparability-human-biological-products-including-therapeutic-biotechnology-derived >. Acesso em: 30 jun. 2022.

UNITED STATES. Food & Drug Administration (FDA). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015. Disponível em: <www.fda.gov/downloads/drugs/guidances/ucm291128.pdf>. Acesso em: 30 jun. 2022

UNITED STATES. Food & Drug Administration (FDA). **Nonproprietary Naming of Biological Products**: Guidance for Industry. 2017. Disponível em: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm459987.pdf>. Acesso em: 16 fev. 2019.

UNITED STATES. Food & Drug Administration (FDA). Training and Continuing Education. 2018b. Disponível em: <<https://www.fda.gov/Training/>>. Acesso em: 15. fev. 2019.

UNITED STATES. Food & Drug Administration (FDA). FDA’s Biosimilar Action Plan (BAP): Balancing action & competition. 2018a. Disponível em: < https://www.fda.gov/media/114574/download>. Acesso em: 01 jul. 2022.